EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation

Amanda Lipsitt, Diego R Hijano, Jose A Ferrolino, Ronald Dallas, Akshay Sharma iD, Gabriela Maron

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31201 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Amanda Lipsitt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Pneumocystis carinii, Pneumonia, Pneumocystis. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Lebanese Syrian Associated Charities, NCI NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pneumocystis jirovecii pneumonia (PJP) in hematopoietic cell transplant (HCT) recipients can be prevented by efficient prophylaxis. We surveyed HCT centers in North America to assess their PJP prophylaxis practices. Most institutions used intravenous (IV) pentamidine (29.6%) or inhaled pentamidine (14.8%); 37% institutions changed from trimethoprim/sulfamethoxazole (TMP‐SMX) to another medication after conditioning; and 44% administered no PJP prophylaxis during the pre‐engraftment period. Most institutions avoided using TMP‐SMX during the pre‐engraftment period, mainly because of concerns about myelotoxicity, despite this being the preferred PJP prophylaxis agent. There is a need to evaluate the effects of TMP‐SMX on engraftment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationPneumocystis cariniiPneumonia, PneumocystisHumansChildTrimethoprim, Sulfamethoxazole Drug CombinationPentamidineMaleAntibiotic ProphylaxisFemaleTransplantation Conditioning

Stichwörter der Autor:innen

Pneumocystis jiroveciihematopoietic cell transplantationprophylaxis

Substanzen

Trimethoprim, Sulfamethoxazole Drug CombinationPentamidine

Autor:innen und Institutionen

  • Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

ORCID-Profile: Akshay Sharma

Förderung

  • American Lebanese Syrian Associated Charities
  • NCI NIH HHS
  • NHLBI NIH HHS
  • National Institutes of Health (NIH)/National Cancer Institute (NCI)
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Lipsitt, A., Hijano, D. R., Ferrolino, J. A., Dallas, R., Sharma, A., & Maron, G. (2024). Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31201

Vancouver

Lipsitt A, Hijano DR, Ferrolino JA, Dallas R, Sharma A, Maron G. Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31201

BibTeX
@article{Lipsitt2024,
  author = {Lipsitt, Amanda and Hijano, Diego R and Ferrolino, Jose A and Dallas, Ronald and Sharma, Akshay and Maron, Gabriela},
  title = {Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31201}
}
Kostenlos starten →